SALIX PHARMACEUTICALS LTD 4

4 · SALIX PHARMACEUTICALS LTD · Filed Jan 14, 2014

Form 4

Period: 2014-01-10

Director

Transactions

Exercise/Conversion
Common Stock
2014-01-10$18.87/sh+22,500$424,575→ 110,024 total
Sale
Common Stock
2014-01-10$91.83/sh−12,000$1,101,960→ 98,024 total
Sale
Common Stock
2014-01-10$92.85/sh−50$4,643→ 97,974 total
Exercise/Conversion
Option to Buy Common Stock
2014-01-10−22,500→ 0 total
Exercise: $18.87Exp: 2014-06-17→ Common Stock (22,500 underlying)

Holdings

Common Stock
(indirect: By Trust)
1,080
Common Stock
(indirect: By LP)
260
Common Stock
(indirect: By Spouse)
6,500
Option to Buy Common Stock
Exercise: $17.63Exp: 2015-06-09→ Common Stock (15,000 underlying)
15,000

Footnotes (4)

[F1]The exercise and sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2013.
[F2]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $91.53 to $92.04, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
[F3]The shares are held by the Rachel L. D'Alonzo Rev Trust U/A DTD 10/24/2001 for which the Reporting Person serves as co-trustee.
[F4]Options are 100% vested.

Documents

1 file